About:
IgA Nephropathy (IgAN, also known as Berger’s disease) is a rare autoimmune disease that can slowly damage the kidneys and may eventually lead to kidney failure. Managing IgAN is challenging—sometimes overwhelming.
Vera Therapeutics is conducting a clinical study in IgAN. The ORIGIN 3 study is exploring how atacicept, the study medication, might help prevent kidney damage in people with IgAN by targeting the upstream source of disease.
Eligibility
-
Are 18 years or older
-
Diagnosed with IgAN, confirmed by a kidney biopsy within the past 10 years
-
On a stable, prescribed regimen of an ACE inhibitor or ARB medication for blood pressure for at least 3 months
**There are other criteria that potential participants must meet in order to qualify for the study**
If you’re interested in participating in one of our Research Studies:
Call
303-232-3366
ext 2150, 2170 or 2190